Press Releases
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
